Core Wealth Advisors Inc. Invests $235,000 in Johnson & Johnson $JNJ

Key Points

• Core Wealth Advisors Inc. invested approximately $235,000 in Johnson & Johnson by purchasing 1,417 shares during the first quarter.
• Several hedge funds have also increased their holdings in Johnson & Johnson, with notable increases such as Focus Partners Advisor Solutions LLC growing its stake by 22.0%.
• Johnson & Johnson reported $2.77 EPS for its last quarter, exceeding estimates, and announced a quarterly dividend of $1.30 per share with a yield of 2.9%.

Core Wealth Advisors Inc. acquired a new stake in Johnson & Johnson (NYSE:JNJ - Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The fund acquired 1,417 shares of the company's stock, valued at approximately $235,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Lantz Financial LLC lifted its position in Johnson & Johnson by 3.3% during the 1st quarter. Lantz Financial LLC now owns 11,974 shares of the company's stock valued at $1,986,000 after purchasing an additional 377 shares during the period. Apexium Financial LP boosted its stake in Johnson & Johnson by 10.7% in the first quarter. Apexium Financial LP now owns 23,989 shares of the company's stock valued at $3,978,000 after acquiring an additional 2,310 shares during the last quarter. Joel Isaacson & Co. LLC grew its holdings in Johnson & Johnson by 3.5% during the 1st quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock worth $12,294,000 after acquiring an additional 2,526 shares during the period. State of Wyoming raised its position in shares of Johnson & Johnson by 205,580.0% during the 4th quarter. State of Wyoming now owns 10,284 shares of the company's stock valued at $1,487,000 after acquiring an additional 10,279 shares during the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. lifted its stake in shares of Johnson & Johnson by 7.0% in the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 73,350 shares of the company's stock valued at $12,164,000 after purchasing an additional 4,816 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.

Wall Street Analysts Forecast Growth

JNJ has been the subject of several research analyst reports. Leerink Partnrs lowered shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Bank of America increased their price target on Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a report on Thursday, July 17th. Citigroup lifted their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the company a "buy" rating in a report on Thursday, August 21st. Leerink Partners cut Johnson & Johnson from an "outperform" rating to a "market perform" rating and lowered their target price for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. Finally, Guggenheim reiterated a "neutral" rating and issued a $167.00 price target (up previously from $164.00) on shares of Johnson & Johnson in a report on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, Johnson & Johnson has an average rating of "Moderate Buy" and an average price target of $176.29.

Johnson & Johnson Stock Performance

NYSE JNJ traded down $0.35 on Wednesday, hitting $177.71. 6,832,001 shares of the stock were exchanged, compared to its average volume of 7,666,583. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $181.16. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The company has a market capitalization of $427.98 billion, a PE ratio of 17.72, a P/E/G ratio of 2.26 and a beta of 0.40. The business's fifty day moving average is $167.02 and its 200 day moving average is $160.33.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm's quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the business earned $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.